Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Official title

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

Overview

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

Detailed description

PRIMARY OBJECTIVE:

I. Determine how polyamine depletion impacts extracellular guanidinoacetate abundance.

SECONDARY OBJECTIVES:

I. Determine the impact of polyamine depletion on polyamine abundance and the global extracellular metabolome within live human gliomas, in situ.

II. Assess the feasibility of longitudinal microdialysis to evaluate pharmacodynamic responses of in situ gliomas to therapeutic intervention in a post-operative setting.

III. Assess the central nervous system (CNS) pharmacokinetics of DFMO and AMXT 1501.

IV. Adverse effects of study drugs in the immediate postoperative setting during microdialysis.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients undergo surgical resection with magnetic resonance imaging (MRI) and placement of catheters for microdialysis at baseline. Patients receive DFMO orally (PO) in combination with AMXT 1501 PO on days 1-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection as well as undergo computed tomography (CT) and collection of blood on study.

ARM II: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO and AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

ARM III: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

Interventions

• Procedure Biospecimen Collection
  Undergo collection of blood
• Procedure Computed Tomography
  Undergo CT
• Drug Eflornithine
  Given PO
• Procedure Magnetic Resonance Imaging
  Undergo MRI
• Drug Polyamine Transport Inhibitor AMXT-1501 Dicaprate
  Given PO
• Procedure Resection
  Undergo surgical resection
• Device Microdialysis
  Undergo Microdialysis
• Procedure Placement
  Undergo placement of catheters

Primary outcome measures

• Change in the tumor/brain extracellular guanidinoacetate ratio [Time frame: Baseline up to 2 months]

Secondary outcome measures (6)

• Measured extracellular levels of glutamate in tumor and brain microdialysates [Time frame: Up to 2 months]
• Proportion of longitudinal microdialysis aliquots containing > 30 uL of microdialysate [Time frame: Up to post-operative day 5]
• Central nervous system free drug levels from microdialysate - DFMO [Time frame: Up to 2 months]
• Central nervous system free drug levels from microdialysate - AMXT 1501 [Time frame: Up to 2 months]
• AMXT 1501 brain/plasma ratio over time [Time frame: Up to 2 months]
• Incidence of adverse events [Time frame: Up to 2 months]

Eligibility criteria

Inclusion criteria

• Age >= 18 years
• Clinical and radiographic evidence suggesting a diagnosis of a diffuse high grade glioma (HGG), or a prior diagnosis of a diffuse glioma
• Planned subtotal resection or biopsy due to tumor location, size, or other clinical indication deemed appropriate by the surgeon
• Provide written informed consent for the current study and the Neuro-Oncology biorepository for archiving of cerebrospinal fluid (CSF) and blood samples collected on this protocol. Willing to remain in the hospital at Mayo Clinic (Rochester, MN) for three days added to their standard post-operative stay to undergo longitudinal microdialysis
• Absolute neutrophil count (ANC) >= 1.5 x 10\^9/L without transfusion within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Platelet >= 100 x 10\^9/L, without transfusion within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Hemoglobin >= 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT) =< 1.5 x upper limit of normal (ULN) (obtained =< 14 days prior to registration)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (obtained =< 14 days prior to registration)
• Total serum bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)
• The patient is clinically euthyroid \[Thyroid Stimulating Hormone (TSH)\]
• Serum creatinine =< 1.5 x ULN or creatinine clearance >= 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above 1.5 x ULN (obtained =< 14 days prior to registration)
• Negative serum or urine pregnancy test is required for female subjects of childbearing age < 14 days prior to registration

Exclusion criteria

• Inappropriate surgical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings
• Vulnerable populations: pregnant or nursing women, prisoners, mentally handicapped
• Unable to swallow tablets or who are at risk for impaired absorption of oral medication. NOTE: This includes but not limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal resection
• Known hypersensitivity or allergy to DFMO or AMXT 1501
• Contraindication to MRI or administration of gadolinium

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Basic science

Study locations

United States · 1 center

• Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT05717153 · 22-005690 · NCI-2022-10375 · R37CA276851

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗